Additional file 3: of Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

MTT assay of combination of RTK inhibitors with cisplatin. Influence of 48 h preincubation with 1.5 μM NVP-AEW541, 1 μM lapatinib or a combination of both compounds on cisplatin sensitivity in HCC38. (DOCX 173 kb

Additional file 10: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Figure S7. Effects of treatment with 19i on primary normal urothelial cells using High Content Analysis-based fluorescent live/dead assay. Percentage of control cell counts of primary urothelial cells (culture # UP281) after 72 h treatment with TMP269 using High Content Analysis-based fluorescent live/dead assay. Data shown are mean from n = 3. (JPG 1137 kb

Additional file 1: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Figure S1. Lentiviral vector used for HDAC4 overexpression. (JPG 2487 kb

Additional file 7: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Figure S5. Expression of HDAC1, HDAC2 and HDAC6 mRNA following treatment of UCCs with 19i or SAHA. Effects of 24 and 48 h treatment with 19i (2 μM), SAHA (2.5 μM) or DMSO as solvent control on mRNA expression of HDAC1, HDAC2 and HDAC6 in VM-CUB1, UM-UC-3 and 639-V cells. All values indicate relative expression compared to a standard for each gene, adjusted to TBP as a reference gene and set as 1 for the solvent control. Significance levels likewise refer to the solvent control (* = p < 0.05). Data shown are mean from n = 3. (PDF 105 kb

Additional file 3 of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Table S2. Antibodies and conditions used for Western blotting. (DOCX 15 kb

Additional file 2: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Table S1. Primers used for PCR. (DOCX 21 kb